

Current prospects and future challenges for nasal vaccine delivery

Yusuf, H., & Kett, V. (2017). Current prospects and future challenges for nasal vaccine delivery. *Human Vaccines & Immunotherapeutics*, 13(1), 34-45. <https://doi.org/10.1080/21645515.2016.1239668>

Published in:
Human Vaccines & Immunotherapeutics

Document Version:
Peer reviewed version

Queen's University Belfast - Research Portal:
[Link to publication record in Queen's University Belfast Research Portal](#)

Publisher rights
© 2016 Taylor & Francis Ltd. This is an Accepted Manuscript of an article published by Taylor & Francis in Human Vaccines & Immunotherapeutics on 09 Dec 2016, available online: <http://www.tandfonline.com/doi/full/10.1080/21645515.2016.1239668>

General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.

1 Current Prospects And Future Challenges For Nasal Vaccine Delivery

2

3 Abstract

4 Nasal delivery offers many benefits over traditional approaches to vaccine administration.
5 These include ease of administration without needles that reduces issues associated with
6 needlestick injuries and disposal. Additionally, this route offers easy access to a key part of
7 the immune system that can stimulate other mucosal sites throughout the body. Increased
8 acceptance of nasal vaccine products in both adults and children has led to a burgeoning
9 pipeline of nasal delivery technology. Key challenges and opportunities for the future will
10 include translating in vivo data to clinical outcomes. Particular focus should be brought to
11 designing delivery strategies that take into account the broad range of diseases, populations
12 and healthcare delivery settings that stand to benefit from this unique mucosal route.

13

14 Key-words nasal, vaccine, needle-free, influenza, mucosal

15

16

17

18 In this review the current state of the art in nasal vaccine delivery will be described along
19 with future prospects. A brief introduction to the anatomy and physiology of the nasal cavity
20 will highlight the advantages and disadvantages of the route. Encapsulation and
21 presentation methods along with particular formulation considerations for the nasal route
22 will also be discussed.

23
24 There are many mucosal routes which have been regarded as potential sites for vaccine
25 delivery such as oral, nasal, pulmonary, conjunctival, rectal and vaginal mucosa. However,
26 for practical and cultural reasons researchers have tended to focus only on oral, nasal, and
27 pulmonary administration.¹ Needle-free vaccines offer many advantages over traditional
28 vaccination approaches including convenience, cost, ease of administration and disposal.

29 There are several needle free methods of vaccination such as transdermal delivery and
30 mucosal delivery.^{2,3} Mucosal immunization has been successfully used in human vaccination.

31 The human mucosal immune system is large and specialized in performing inspection for
32 foreign antigens to protect the surfaces themselves and of course human body interior.
33 Since most infections affect or start from mucosal surfaces, using a mucosal route of
34 vaccination is of great interest and provides a rational reason to induce a protective immune
35 response.³ Nasal delivery of vaccine offers an easily accessible route to the immune system.

36 The nose has the function of olfactory detection (sense of smell) and also filtration,
37 humidification and temperature control of air as it enters the respiratory system. Moving
38 from front to back the areas of the nasal cavity are the nasal vestibule, the respiratory
39 region, and the olfactory region. The nasal cavity is divided by the septum to form the left
40 and right nares, which lead into the left and right choana before opening onto the
41 nasopharynx at the top of the throat. The turbinates bound the nasal walls and are
42 responsible for air conditioning and the large mucosal surface area of the nasal cavity. The
43 nose is also the main port of entry for many pathogens. The first barrier to foreign bodies is
44 hair at the entrance to the nares, the nostrils, which successfully keeps out larger particles.
45 The entire surface of the nasal cavity is covered in a mucus layer, which traps smaller
46 particles. Mucus is an aqueous, viscoelastic and adhesive gel⁴ that contains several types of
47 mucins (abbreviated to MUC) MUC1, MUC4, MUC5A and MUC5B, MUC16, that are
48 produced by either goblet cells or mucus subglands.^{5,6} Cilia perform a mechanical clearing
49 role termed mucociliary clearance by beating and thus transporting the mucus blanket with
50 entrapped pathogens to the back of the throat at a rate of 5-6 mm per minute, either to be
51 destroyed in the stomach or expectorated via sneezing and/or coughing. This function

minimises the amount of particles able to enter the body through the mucosal surface.⁷ The nasal route has been used to deliver vaccines for respiratory infections and sexually transmitted infections.⁸ The rationale for targeting mucosal tissue in the genital tracts can be attributed to the mucosal immune system.

The Mucosal Immune System

The mucosal immune system provides local protection against pathogens that enter the body through the mucosal membranes. The mucosal immune activities are associated with lymphoid tissues, i.e. mucosa-associated lymphoid tissue (MALT), which is present in mucosal tissue in the nose, lungs, gastrointestinal tract and vaginal/rectal surfaces.⁹ The MALT is classified into specific subcompartments, depending on the location, including the gut-associated lymphoid tissue (GALT), nasopharynx-associated lymphoid tissue (NALT),¹⁰ bronchus-associated lymphoid tissue (BALT). The mucosal routes commonly used for vaccination strategies are depicted in Figure 1. The mucosal immune systems are protected by immune cells that populate the region along the mucosal surfaces, and also epithelial cells and mucus that acts as physical barrier before the pathogen gain access to the underlying tissues.

[Figure 1 near here]

Respiratory Epithelial Cells

The epithelial cell layers cover the mucosal surfaces including the respiratory, gastrointestinal and urogenital tracts exposed to the outer environments. The epithelial cell layer acts as a barrier that is equipped with some supporting elements such as the mucus and cilia in preventing penetration of pathogens (Figure 2).

Furthermore, the epithelial cells can detect and uptake pathogenic organisms and/or antigenic components by performing nonspecific endocytosis or interacting with pattern recognition receptors such as Toll-like receptors (TLRs).¹¹⁻¹⁴ The epithelial cells together with lymphocytes and underlying antigen presenting cells (e.g. dendritic cells (DCs) and macrophages), cytokines and chemokines perform an innate, non-specific and adaptive immune response to encounter the invasion of pathogenic organisms or immunogenic substances.^{14,15}

[Figure 2 near here]

Nasopharynx-Associated Lymphoid Tissue (NALT)

The NALT can be simply defined as organized mucosal immune system in the nasal mucosa that consist of lymphoid tissue, B cells, T cells and antigen presenting cells (APCs) and are covered by an epithelial layer containing memory (M) cells.¹⁶ M cells are present in the epithelial cell layers and have specialization in transporting antigen across the epithelium.^{17,18}

Whenever the nasal mucosa is exposed to pathogens or antigenic substances, the intruder will interact with the mucosal immune system. The type of interaction is highly dependent on the characteristics of the antigen. The pathogen or immunogenic substances may be able to pass through the nasal epithelium and interact with the APCs such as macrophages and DCs. These APCs will process the antigen and migrate to the lymph node where the immunogenic portion will be presented to the T cells. This marks the activation of the immune response cascade. A soluble antigen might be recognized by the APCs,¹⁹ while particulate antigen is generally taken up by the M cells and transported to the NALT.²⁰ The NALT is also drained to the lymph node where further antigen processing will occur. A schematic representation of this process in more detail mechanisms is presented in Figure 3²¹.

[Figure 3 near here]

Immunoglobulin A (IgA)

In addition to the MALT, the mucosal immune system also produces the antibody immunoglobulin A (IgA), that plays an important role in mucosal immunity at mucosal surfaces.²² IgA constitutes up to 15 % of the total immunoglobulin, which is predominantly present in external secretions including the mucus in the bronchial, urogenital and digestive tracts, saliva and tears.²³ It was found that the production of IgA in humans could be over 1 mg/ml in secretions associated with the mucosal surfaces.¹⁸ A small amount of IgA can be found in the serum while most of the IgA is located in external secretions known as secretory IgA (sIgA).²⁴ IgA consist of a dimer or tetramer, a joining J-chain polypeptide and a polypeptide chain called the secretory component.^{24, 25} IgA has several functions in mucosal defense including the entrapment of antigens or pathogens in mucus to prevent them from direct contact with the mucosal surface.^{15, 26} In addition, sIgA may also block or provide steric hindrance to surfaces of pathogenic molecules that may inhibit their attachment to the epithelium.²⁷

The predominance of IgA in mucosal areas is a result of mutual collaboration between plasma cells and epithelial cells. The activated plasma cells in the lamina propria, adjacent to mucosal surfaces produce polymeric IgA (pIgA), while the epithelial cells in the mucosal surfaces express an Ig receptor called the polymeric Ig receptor (pIgR). The released pIgA from activated plasma cells binds to pIgR, and is then taken up into the cell via endocytosis. IgA is transported across mucosal epithelial cells before being released onto the luminal surface of the epithelial cells. Proteolysis cleavage of the pIgR allows IgA to be secreted into mucosal secretions.^{15, 25, 28}

Mucosal Vaccines

New vaccine formulations should be able to induce innate and adaptive immune response; involving antigen-specific memory T and B cells that will respond effectively to the invading pathogens.^{29, 30} Interaction with pathogens or antigens can produce the IgA secretion as an antibody response.³¹ Intracellular antigens, can be produced by invading viruses that replicate within the host cell, or derive from cytoplasmic bacteria, while the extracellular antigens include bacteria, parasites, and toxins in the tissues. Intracellular antigens are generally processed in the host cells, coupled to a major histocompatibility complex-I (MHC-I), a cell surface molecule, and transported to the cell surface.^{32,32} The presence of MHC-I on the cell surface will lead to activation of CD8+ T-cells to become cytotoxic T-lymphocytes (CTLs). Extracellular antigens are endocytosed and presented on MHC-II molecules for activation of CD4+ T-helper (Th) cells.³²⁻³⁴

The activation of Th cells will release a specific set of cytokines that modulate the B cell and CD8+ CTL immune response, depending on the nature of the stimulant.³⁵ Th cell types Th-1, Th-2 or Th-17 will be induced accordingly. A Th-1 response develops in the presence of interleukin 12 (IL-12), which is in turn synthesized primarily by DCs and/or natural killer (NK) cells in the presence of bacteria or virus. The Th-1 response is marked by the production of the Th-1 cytokines e.g. interferon-gamma (IFN- γ) and tumour necrosis factor-beta (TNF- β). A Th-2 response is driven by the presence of IL-4 and results in the production of specific cytokines IL-4, IL-5, IL-9 and IL-13.³⁶ It can be seen that the production of IL-4 generates a feedback loop that results in increased generation of a Th-2 response at the local site.

Nasal vaccination can also result in stimulation of Th-17 CD4+ cells. Th-17 cells are responsible for the secretion of the proinflammatory interleukins IL-17A and IL-22, as well as

IL-17F and IL-21. It is known that the Th-17 family of cytokines respond to extracellular bacterial and fungal pathogens, and Th-17 cells enhance generation of Th-1 cells through an increased IFN- γ activation giving rise to a Th-1/Th-17 immune response that activates macrophages and other innate responses.³⁶⁻³⁸ Stimulation of epithelial cells by the Th-17 family of cytokines can aid tissue repair and secretion of antimicrobial peptides, which can exert a protective effect in pulmonary infection.³⁹ There is contradictory evidence, however, regarding the role of Th-17 response in nasal immunization. Early work on the role of Th polarization in nasal immunization indicated that this route always promotes a Th-17 response.⁴⁰ Later research has indicated that the response is more nuanced, with some contradictory evidence regarding advantages and disadvantages of IL-17A induction.^{41,42, 43} Predominance of one set of cytokines over the other is generally indicative of polarization of Th responses, for example the presence of IL-4 and absence of IFN- γ indicate a classical Th-2 polarized immune reaction⁴⁴ although these cytokines can also be released at the same time.^{45,46, 47} The varying cytokine profiles related to CTL and antibody production are fundamental in affording protection against a specific pathogen. Specific macrophage activation was found to play a crucial role in the eradication of *Mycobacterium tuberculosis* bacterial infections,⁴⁸ showing that the induction of specific immune responses may play a key role in determining whether a given vaccine product is effective.

The recently discovered innate lymphoid cells (ILCs) act as an early source of cytokines to regulate and direct mucosal immune responses.⁴⁹ Unlike B or T cells, however, they do not exhibit antigen specificity. Group 1 ILCs (ILC1s) include NK cells and produce Th-1 type cytokines IFN- γ and tumor necrosis factor- α (TNF- α); group 2 ILCs (ILC2s) produce Th-2 type cytokines IL4, IL-5 and/or IL-13, while group 3 ILCs (ILC3s) include lymphoid tissue inducer cells that produce Th-17 type cytokines IL-17 and/or IL-22. Both ILC1s and ILC3s have been implicated in type 1 and Th17 cell-mediated immunity and disease.⁵⁰ Because they are involved in early release of cytokines at mucosal sites, ILCs have been implicated in directing immune response at the mucosal surface, as shown by a number of recent studies.^{51, 52} NK cells and ILC1-like cells damped the immune response after vaginal administration of ovalbumin and cholera toxin to mice.⁵³ NK cells have been shown to enhance Th proliferation through IFN- γ production,⁵⁴ while ILC2s play a role in directing Th-2 response.⁵⁵ There is also evidence that ILCs can act as APCs, although this may be specific to the lymphoid tissue site involved and is thought to occur to a lesser extent than through the professional APCs.⁵⁵ Finally the regulatory T-cells (Tregs) play a role in ILC and Th

communication,⁵⁴ as well as helping to directly control Th response, which is particularly important in autoimmune dysfunction discussed later.⁵⁶

Advantages of nasal vaccine delivery

The nasal route has great potential for vaccination due to the organized immune systems of the nasal mucosa. The nasal epithelium encloses follicle-associated lymphoid tissues that are important in inducing mucosal immune response. The immune cells such as nearby B-cells can produce IgA at the mucosal sites where the respiratory pathogens invade.⁵⁷ Many published studies have shown that nasally administered vaccines induce serum IgG and mucosal IgA that are important for deliberating enhanced efficacy of vaccine.^{57, 58} The enhanced induction of mucosal IgA antibodies has been shown to play a significant role in neutralizing pathogens such as *Streptococcus pneumonia*⁵⁹ and measles viruses⁶⁰ and preventing further infection. Moreover, intranasal immunization has also been reported to induce cross-reactive antibodies that might be indicative of cross-protection.^{61, 62} This effect can make vaccines more efficient by reducing the number of vaccinations required since cross-protective vaccines may produce cross-reactive antibodies that recognize more than one antigen. Given the high cost of many antigen production systems this offers a distinct advantage over other routes.

Therapeutic vaccines

While much of the work on nasal vaccine delivery is currently focused on prophylactic vaccines, the access that the nasal route provides to the mucosal immune system also has relevance for therapeutic vaccines used to treat rather than prevent disease. Nasal immunotherapy for treatment of various cancers and Alzheimer's are currently generating much interest.^{63,64} A particular focus is the use of therapeutic vaccines for the treatment of autoimmune diseases such as type I diabetes, atherosclerosis, multiple sclerosis, rheumatoid arthritis, lupus and Crohn's disease. These are caused by unchecked immune response to molecules, termed self-antigens, that are capable of inducing an immune response in a host but should not induce an immune response in a healthy individual that produces them, whereas undesirable response to innocuous environmental antigens gives rise to allergy. The autoimmune and inflammatory response is governed by regulatory T-cells (Tregs), with poor function or reduced numbers of Tregs being associated with autoimmune disease. Treatments for this family of diseases are often non-specific, or use immune suppressants that increase susceptibility to infection. Development of effective therapeutic vaccine would correct the inappropriate immune response through generation of tolerance to the self-antigen(s).⁶⁵ Treg cells that express the forkhead box P3 transcription factor are known as FoxP3+T-cells, with dysfunction of this subset of Tregs being implicated in a range of chronic inflammatory disorders.⁶⁶ It has long been known that oral delivery is effective in generating antigen tolerance, through deliberate introduction of the antigen to food.⁶⁷ More recently it has been shown that a similar tolerance induction can be achieved via nasal delivery through activation of the DCs in the draining lymph nodes to enhance induction of FoxP3+T-cells.⁶⁸ Examples of successful nasal delivery include immunization to suppress atherosclerosis^{69,70} and arthritis.⁷¹ The effect of adjuvant on tolerance is discussed in a later section.

Formulation approaches

Current nasal formulations include, solutions (drops or sprays), powders, gels and solid inserts.⁷² Solutions are often described in the literature as they are both the easiest way of formulating a vaccine for an in vivo study or clinical trial, and are the easiest to administer for example in mice where the liquid is often pipetted directly into the nostril. In humans this often means that the subject either has to remain laying down or with their head held back for a period of time after administration, which is not realistic in a mass vaccination setting. Sprays are easier to administer and deliver vaccine further into the nasal cavity, but

may still leak out of the nostril or drip into the oral cavity. Including a gelling agent in the formulation that is either mucoadhesive or able to penetrate through mucus offers increased residence time, while advantages of solid formats such as powders or solid inserts include ease of manufacture and stability, while liquids are more prone to degradation. Taste may also be a factor as formulations may travel into the oral cavity, although given that vaccines tend to be administered once or twice only, this is less of an issue than for medicines that are taken on a regular basis.

A range of naturally-occurring, synthetic and semi-synthetic polymers have been investigated as gelling agents in nasal delivery of vaccine. Administering as a gel should improve retention, although there is ongoing debate as to whether positively charged or anionic polymers offer better uptake. Those that have the ability to adhere to mucosal surfaces and selectively target M cells or APCs, should be the most effective.^{18, 26} Chitosan has been much investigated, and is a polysaccharide manufactured from chitin found in crustacean shells or fungi by a deacetylation process. Because of the range of sources this polymer is available in a range of molecular weights, but all are made up of repeating units of glucosamine and N-acetylglucosamine and bear a positive charge making it mucoadhesive. Varying the degree of deacetylation affects the charge, as does methylation. Methylating chitosan offers some advantages for mucosal delivery.

Powder formats have the advantage of increased stability over their liquid counterparts and ability to target further into the nasal cavity. An example of this is the Anthrax spray-dried powder formulation suitable for mass vaccination in developed and developing world settings.⁷³ Possible disadvantages of powders include the ease and cost of administration if specialist applicators are required. Solid inserts are tablets designed to dissolve when in contact with mucus and have been investigated for vaginal delivery in humans and nasal delivery in livestock animals,^{74,75} and have many similarities with sublingual formulations.

Soluble antigens tend to be less immunogenic than particulate formulations, additionally encapsulating antigen into particles may improve the transport of the antigens across the nasal mucosa. For this reason there has been a great interest in developing particulate systems as carriers for vaccine products.⁷⁶⁻⁷⁸ Aspects such as vaccine formulations and delivery strategies are important in designing new vaccines so that efficient induction of the innate and adaptive immune response can be obtained according to the target pathogen.^{18,}

²⁶ Particulate delivery systems that can imitate pathogens such as polymeric nanoparticles and liposomes are considered a promising approach for nasal vaccine delivery.

Nanoparticles are particles in the nanometer 1×10^{-9} m size range and can be made of polymers such as chitosan, alginate or synthetic co-polymers such as poly(lactic-co-glycolic acid (PLGA). Varying the molecular weight and/or ratio of lactic to glycolic acid affects the rate of degradation enabling rate of release to be controlled. But PLGA nanoparticles bear a negative charge, which is not compatible with mucosal delivery, hence the plethora of papers investigating various coatings or modifications to adjust this. Those with positive charge and enhanced residence have tended to give the best immunological responses with high serum antibody titers and sIgA levels.⁷⁹ Poly(lactic acid) (PLA) and polyethylene glycol (PEG) can also be combined to form co-block polymers able to incorporate antigen⁸⁰, varying the molecular weight of the PEG and/or ratio of PEG to PLA alters physicochemical characteristics, release and hence efficacy.⁸¹

Other polymers investigated include pullulan, a naturally occurring polysaccharide copolymer made up of maltotriose subunits from fungus;⁸² pectin, a naturally occurring polysaccharide found in fruits; and the biodegradable synthetic polymer polycaprolactone.⁸³

Liposomes are nano- or micrometre sized particles made up of one or more lipid bilayers, which have the ability to incorporate antigen at their surface or inside the aqueous core. There are numerous examples of coated and un-coated liposomal formulations used to deliver vaccine intranasally in a range of formats.⁸⁴⁻⁹⁰ Chen showed that trimethylchitosan-coated liposome powders offered improved uptake in ex vivo nasal penetration studies when compared with the same liposomes coated in chitosan.⁹¹ Liposomes that also comprise lipid or other material derived from virus are known as virosomes, with material from influenza virus such as hemagglutinin (HA) and neuraminidase being commonly used.

⁹²⁻¹⁰²

Currently there is more evidence to support the hypothesis that particles smaller than 300nm are the most effective at crossing mucus,¹⁰³ but there is also evidence to suggest that larger particles are also able to penetrate. Results from intranasal administration of mucoadhesive microparticles suggest that penetration of the entire particle may not be necessary to induce an immune response.¹⁰⁴ It is likely that the overall combination of size and charge are key to achieving maximum immunological effect. Some examples of particulate delivery systems investigated for nasal delivery of vaccine are shown in Table 1.

[Table 1 near here]

Adjuvants

Some materials added to form gels or particles may act as adjuvants as well as delivery vehicles. Alternatively, adjuvants may be added as a separate component to a vaccine product. Adjuvants are materials added to a vaccine to boost the immune response and may also reduce the amount of antigen required to elicit an immune response. Alum is often used in traditional vaccines but is not effective when administered mucosally. Judicious choice of adjuvant can direct the arm of the immune system, as described previously. Often particulate delivery systems are believed to confer both the benefits of optimised delivery across mucus/mucosal tissue and inherent adjuvanting effects. Many studies have investigated these abilities and ascribed immune boosting response to one, other or both qualities.²⁶

Mucosal adjuvants that have been tested for intranasal vaccine delivery including: MF59 emulsion (containing squalene oil, the surfactants Span 85 and Tween 80 and citrate buffer)^{105, 106}, lipopolysaccharide,^{84, 107} TLR agonists,^{41,108,109} chitosan,¹¹⁰ trimethylchitosan,^{91 110} bacterial outer membrane protein¹¹¹ and cholera toxin¹¹² or heat-labile enterotoxin (LT) from *E.coli*.¹¹³ Some side effects have been found with the use of bacterial toxin when given intranasally, including Bell's palsy (Facial paralysis) and other adverse events related to disorders of the facial nerves.¹¹⁴⁻¹¹⁶ It has been suggested that the central nervous system was involved in the palsy as the bacterial toxin was re-directed into the brain.^{115, 117} Thus, the use of LT as vaccine adjuvant is no longer recommended. Mast cell activators such as compound 48/80 (C48/80) have shown promise in Anthrax vaccine.⁷³ As described previously, adjuvants can help to polarize immune response and this effect should be taken into account when considering adjuvant for a particular vaccine type. Mice immunized with an influenza vaccine adjuvanted with a synthetic TLR-4 agonist via the nasal route, exhibited a transient, enhanced IL-17A pathology, characterised by weight loss and morbidity, which was significantly greater than observed in mice given no-adjuvanted antigen.⁴¹ The effect of adjuvants on induction of tolerance has also been noted; an intranasal co-administration of hen egg lysozyme with a TLR2 ligand enhanced Th1-type antibodies in one case,¹¹⁸ while another TLR2 ligand, Pam3Cys, was shown to increase the risk of developing autoimmune disease.¹¹⁹ PLGA nanoparticles have been shown to boost tolerance in suppression of arthritis¹²⁰ and further research by the same group has shown that they are responsible for generation of enhanced Treg cell induction.⁶⁸

Current nasal vaccine products

Licensed intranasal vaccines for humans include the influenza vaccines FluMist/Fluenz™ (MedImmune, MD, USA)¹²¹ and the Nasovac™ live attenuated influenza nasal spray manufactured by the Serum Institute of India, which was developed alongside its live attenuated A(H1N1), more commonly known as swine flu.¹²² No serious side effects have been reported associated with the administration of Nasovac indicating its safety,¹²³ although its efficacy data are not sufficiently available yet.¹²⁴ Until recently FluMist was considered one of the most successful intranasal vaccines, it is well tolerated and had exhibited good efficacy.¹²⁵ A runny nose/nasal congestion has been reported as the most common adverse events of Flumist, with mild to moderate in severity.¹²¹ However The US CDC (Centre for Disease Control) Advisory Committee on Immunization Practices (ACIP) recently voted that the Flumist nasal spray live attenuated influenza vaccine (LAIV) (sic), should not be used during the 2016-2017 flu season, based on “data showing poor or relatively lower effectiveness of LAIV from 2013 through 2016”.¹²⁶ At the time of writing no further detail was available. It should be noted that a nasal Live Attenuated Influenza Virus (LAIV) influenza vaccine has been used for over 50 years in Russia and previously the USSR. Data published from a study using the Russian intranasal vaccine showed better herd immunity for intranasal LAIV than inactivated vaccine.¹²⁷ Herd immunity is a crucial impact of mass vaccination programs; it is the immunity given to the whole population, even those who have not received a vaccine, because enough of the population (the herd) have received the vaccine that the infection cannot effectively spread. However, it should be noted that the Russian LAIV is administered in 2 doses 3 weeks apart, which increases cost and has the possibility of reducing compliance.

Targeting school age children for influenza has two benefits, first this age group tend to have the highest rates of influenza infection. Secondly targeting children reduces infection rates in through transmission from this group, although transmission rates can vary.¹²⁸ In the European Union an intranasal influenza vaccine was licensed in 2011. Damm et al explored the possible effect of introducing this product in Germany and concluded that introducing the vaccine to German schoolchildren would lead to a “substantial reduction in influenza-associated disease at a reasonable cost to the German statutory health insurance system”.¹²⁹ Researchers looking into the same question for Thailand reached similar conclusions with provisos based on willingness to pay and contact between age groups.¹³⁰ This study raised the issue of effectiveness across countries where healthcare systems are

either new or emerging and differences in rates and timing of seasonal outbreaks. These findings highlight the differences between high and low- to middle-income countries and demonstrate the need to carefully evaluate the target population and seasonal factors before designing or selecting a vaccine product.

[Table 2 near here]

A recent review describes most of the commonly encountered nasal delivery devices currently on the market.⁷² Additionally, there is a range of nasal delivery strategies at various stages along the pre-clinical-clinical pipe-line, some of these may be suitable for vaccine delivery either in their current formats or with some adaptation. A selection of these is shown in Table 2 and will be described briefly. Criticalsorb is a penetration enhancing formulation based on PLGA and PLA, developed by a spin-out from University of Nottingham, UK, currently there are no details for vaccine application. The web-site of μ co™ System (Muco System) shows data for a nasal flu vaccine in a non-human primate immunogenicity study, stating that more sIgA was produced in the mucosal membrane compared to injection and nasal liquid spray. and 4-times greater sIgA than a nasal liquid spray.¹³¹ Optinose is a breath-actuated device for delivering powder or liquid, a schematic of the device has been published in the literature,¹³² as has data on the use of sumatriptan delivered via the Optinose device^{133, 134}. Kurve is a device for delivering liquid formulations “via a controlled, turbulent flow”,¹³⁵ the makers have published results of a pilot clinical trial detailing their intranasal insulin therapy for Alzheimer’s disease and amnesic mild cognitive impairment A,¹³⁶ while Archimedes Pharma developed a chitosan-based formulation, ChiSys®, that achieved good success in a clinical trial for a Norovirus vaccine.¹³⁷ Because of the proprietary and often pre-approval nature of the devices described (with the exception of Flumist/Fluenz and MAD Nasal), there is a paucity of information regarding design of some of the devices described in this section. The interested reader is referred to the relevant company web-sites (Table 2), which will offer more current information than is possible in this review.

Conclusion

Safety profiles are yet to be established in humans for many of the formulation approaches described in this review. However, the ever-increasing range of clinical trials indicates the accepted need for nasal vaccines that are easy to administer and offer improved benefits

over other mucosal routes in terms of cost of formulation and need for skilled personnel to administer. The obvious benefits of directly stimulating the mucosal immune response are clear, but as yet have not been fully realized with the exception of those for influenza, which demonstrate the efficiency of this route. The recent US CDC press release will no doubt impact on the pharmaceutical industry view of riskiness of nasal formats. But with increased need to immunize large populations, potentially in swift response to pandemics such as avian, swine flu and Ebola there is a clear need to have strategies in place. The interplay between formulation or carrier and adjuvant in directing immune response should be investigated. Unfortunately, the high cost of clinical trials and issues with correlating immune responses in animal models with humans have created a bottleneck. There is a growing body of evidence to suggest that genetic material can be successfully delivered via this route, while recent studies have also demonstrated the advantages associated with combining the nasal with other routes of delivery or even combining vaccine with microbicide.¹³⁸ This review has focused primarily on prophylactic vaccines but there is encouraging evidence that nasal delivery will have a role to play in the design of therapeutic vaccines for e.g. cancers Alzheimer's and autoimmune diseases. The role of presentation is also important when designing pre-clinical studies – instillation of drops is relatively facile even in mice, while more advanced formulations require more careful consideration than those administered via pipette. The design of ex vivo, cell culture or tissue models that provide better prediction of response in humans is extremely desirable. A “one size fits all” approach is not appropriate for vaccine design where factors relating to target population, disease type and mode of infection, will all impact on both formulation and antigen optimization.

435 Table 1 Examples of particulate formulations with published in vivo data.
436

Particle type	Vaccine	Study type	Key findings	Literature source
Chitosan and HSA (human serum albumin)	Hepatitis B Plasmid DNA	Female C57/BL mice compared with plasmid DNA alone and protein antigen	humoral and mucosal immune response	Lebre et al 2016 ¹³⁹
polycaprolactone /chitosan	Hepatitis B surface antigen (HBsAg)	C57BL/6 mice IN only. Varying doses of HBsAg no comparator formulations	Dose-independent serum IgG and nasal IgA	Jesus et al 2016 ⁸³
TMC	ovalbumin compared with PLGA and TMC-coated PLGA	Female Balb/c compared with PLGA and TMC-coated PLGA (IM and IN)	Serum IgG superior to other IN but inferior to all IM	Slutter et al 2010 ⁷⁹
chitosan and glycol chitosan coated PLGA	HBsAg	Female BALB/c mice compared with chitosan coated PLGA and PLGA, HBsAg-Alum sub-cut.	GC-PLGA NPs could induce significantly higher systemic and mucosal immune response than other IN nanoparticles.	Pawar et al 2013 ¹⁴⁰
PEG-PLA	HBsAg	BALB/c mice compared with PLA nanoparticles and conventional alum-HBsAg based vaccine	Higher systemic and mucosal response than PLA	Jain et al 2009 ⁸⁰
Liposomes	Influenza plasmid DNA (H1N1) hemagglutinin (HA)	BALB/c mice challenge study IN compared with IM DNA alone (IN and IM)	Protective effect against challenge	Wang et al 2004 ⁸⁵
Esterified hyaluronic acid microparticles	Commercial Influenza H1N1 HA and LTK63 or LTR72 adjuvants	mice, rabbits and micro-pigs IN compared with soluble HA + LTK63, or IM with HA	Significantly enhanced serum IgG responses and higher hemagglutination inhibition (HI) titers than other groups	Singh et al 2001 ¹⁰⁴
Glycol chitosan coated liposomes	Hepatitis B Plasmid DNA	BALB/c mice prime boost	Humoral mucosal and cellular	Khatrri et al 2008 ¹⁴¹

		compared with DNA alone (IN) and HBsAg protein (IM)	response higher than DNA alone. Cellular response better than IM protein antigen	
Liposomes/hyaluronic acid	<i>Yersinia pestis</i> (plague)	C57BL/6 mice No IM comparison	Th1/Th2 humoral immune response	Fan et al 2015 ⁹⁰
Chitosan-coated PLGA	foot-and-mouth disease plasmid DNA	Challenge study in cattle	Higher mucosal, systemic, and cell-mediated immunity than Chitosan - Inactivated antigen nanoparticles	Pan et al 2014 ¹⁴²
Cationic cholesteryl-group-bearing pullulan	<i>Clostridium botulinum</i> type-A neurotoxin subunit antigen	BALB/c mice	Strong tetanus-toxoid-specific systemic and mucosal immune responses	Nochi et al 2010 ⁸²

437

Name	Company	Presentation	Drug type	Regulatory status	Marketed products	Company web-site
Criticalsorb	Critical Pharmaceuticals	Powder or aerosol	Small molecule – peptide, HGH, insulin	GRAS status?	None	www.criticalpharmaceuticals.com
μco™	Nasal Delivery System Business	Powder-based mucoadhesive drug carrier plus device	Anti-emetic Migraine, flu vaccine	Phase II, Phase I, pre-clinical	None	www.snb-inds.co.jp/en/
Optinose	Optinose	Powder or liquid plus device	Small molecule	Clinical trials (various)	None	optinose.com/
Kurve	Kurve	Liquid plus device	Includes Alzheimer's vaccine	Phase II	None	www.kurveotech.com
MAD nasal	Teleflex	Liquid plus device	Attachment for syringe to atomize liquids	Device only/ not vaccines	Marketed as stand-alone device	www.teleflex.com
None	Drug Delivery International	Solid insert	Small molecules & insulin	None found	None found	www.bddpharma
Flumist Fluenz	MedImmune (AstraZeneca)	Nasal gel	Flu vaccine	FDA & EMA	Flumist Fluenz	www.flumistquadrivalent.com/
Bacterial S antigen pores	Tufts University - US	Oral/nasal format not stated	Tetanus toxin and rotavirus VP6 antigen	None	None	www.tufts.edu/
Vaccinetab	Queen's University Belfast, UK	Liposomal liquid, powder or nasal insert	Small molecules and antigen	GRAS	None	www.vaccinetab.com
ChiSys	Archimedes Pharma	Nasal gel	Small molecules and antigen	Phase I, pre-clinical	Small molecule	

440

441

Figure Captions

Figure 1. Routes of mucosal vaccination within the mucosa-associated lymphoid tissue (MALT), with several subcompartments including: the nasopharynx-associated lymphoid tissue (NALT), bronchus-associated lymphoid tissue (BALT), gut-associated lymphoid tissue (GALT) and genital tract-associated lymphoid tissue, reproduced from Lycke et al, 2012.¹²⁵

Figure 2. Structure and function of respiratory epithelial cells; equipped with mucus layer (not shown) and ciliated cells, reproduced from Grassin-Delye (2012)¹⁴³.

Figure 3. Pathways demonstrating how particulate antigen triggers local immune response in the nasal mucosa and systemic immune response via the NALT, adapted from Csaba (2009)²¹.

455

456

- 457 1. Giudice EL, Campbell JD. Needle-free vaccine delivery. *Adv Drug Deliv Rev* 2006; 58:68-89.
- 458 2. Chen D, Endres RL, Erickson CA, Weis KF, McGregor MW, Kawaoka Y, Payne LG. Epidermal immunization by a needle-free powder delivery technology: immunogenicity of influenza vaccine and protection in mice. *Nat Med* 2000; 6:1187-90.
- 459 3. Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. *Nat Med* 2005; 11:S45-S53.
- 460 4. Quraishi MS, Jones NS, Mason J. The rheology of nasal mucus: a review. *Clin Otolaryngol* 1998; 23:403-13.
- 461 5. Voynow JA, Rubin BK. Mucins, mucus, and sputum. *Chest* 2009; 135:505-12.
- 462 6. Thornton DJ, Rousseau K, McGuckin MA. Structure and function of the polymeric mucins in airways mucus. *Annu Rev Physiol* 2008; 70:459-86.
- 463 7. Walker WT, Liew A, Harris A, Cole J, Lucas JS. Upper and lower airway nitric oxide levels in primary ciliary dyskinesia, cystic fibrosis and asthma. *Respir Med* 2013; 107:380-6.
- 464 8. Thomann-Harwood LJ, Kaeuper P, Rossi N, Milona P, Herrmann B, McCullough KC. Nanogel vaccines targeting dendritic cells: Contributions of the surface decoration and vaccine cargo on cell targeting and activation. *J Controlled Release* 2013; 166:95-105.
- 465 9. Brandtzaeg P. Function of Mucosa-Associated Lymphoid Tissue in Antibody Formation. *Immunol Invest* 2010; 39:303-55.
- 466 10. van de Pavert SA, Mebius RE. New insights into the development of lymphoid tissues. *Nat Rev Immunol* 2010; 10:664-74.
- 467 11. Hargreaves DC, Medzhitov R. Innate Sensors of Microbial Infection. *J Clin Immunol*; 25:503-10.
- 468 12. J Philpott D, E Girardin S, J Sansonetti P. Innate immune responses of epithelial cells following infection with bacterial pathogens. *Curr Opin Immunol* 2001; 13:410-6.
- 469 13. López-Boado YS, Wilson CL, Hooper LV, Gordon JI, Hultgren SJ, Parks WC. Bacterial Exposure Induces and Activates Matrilysin in Mucosal Epithelial Cells. *The Journal of Cell Biology* 2000; 148:1305-15.
- 470 14. Kagnoff MF, Eckmann L. Epithelial cells as sensors for microbial infection. *J Clin Invest* 1997; 100:6-10.
- 471 15. Neutra MR, Mantis NJ, Kraehenbuhl J-P. Collaboration of epithelial cells with organized mucosal lymphoid tissues. *Nat Immunol* 2001; 2:1004-9.
- 472 16. Kiyono H, Fukuyama S. NALT- versus PEYER'S-patch-mediated mucosal immunity. *Nat Rev Immunol* 2004; 4:699-710.
- 473 17. Corr SC, Gahan CC, Hill C. M-cells: origin, morphology and role in mucosal immunity and microbial pathogenesis. *FEMS Immunol Med Microbiol* 2008; 52:2-12.
- 474 18. Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. *Nat Rev Immunol* 2006; 6:148-58.

- 501 19. Sharma S, Mukkur TK, Benson HA, Chen Y. Pharmaceutical aspects of
502 intranasal delivery of vaccines using particulate systems. *J Pharm Sci* 2009;
503 98:812-43.
- 504 20. Illum L. Nanoparticulate systems for nasal delivery of drugs: A real
505 improvement over simple systems? *J Pharm Sci* 2007; 96:473-83.
- 506 21. Csaba N, Garcia-Fuentes M, Alonso MJ. Nanoparticles for nasal
507 vaccination. *Adv Drug Deliv Rev* 2009; 61:140-57.
- 508 22. Fagarasan S, Honjo T. Intestinal IgA synthesis: regulation of front-line
509 body defences. *Nat Rev Immunol* 2003; 3:63-72.
- 510 23. Macpherson AJ, Slack E. The functional interactions of commensal
511 bacteria with intestinal secretory IgA. *Current opinion in gastroenterology* 2007;
512 23:673-8.
- 513 24. Yel L. Selective IgA Deficiency. *J Clin Immunol* 2010; 30:10-6.
- 514 25. Snoeck V, Peters IR, Cox E. The IgA system: a comparison of structure and
515 function in different species. *Vet Res* 2006; 37:455-67.
- 516 26. Borges O, Lebre F, Bento D, Borchard G, Junginger HE. Mucosal Vaccines:
517 Recent Progress in Understanding the Natural Barriers. *Pharm Res* 2010;
518 27:211-23.
- 519 27. Hutchings AB, Helander A, Silvey KJ, Chandran K, Lucas WT, Nibert ML,
520 Neutra MR. Secretory Immunoglobulin A Antibodies against the $\sigma 1$ Outer Capsid
521 Protein of Reovirus Type 1 Lang Prevent Infection of Mouse Peyer's Patches. *J*
522 *Virol* 2004; 78:947-57.
- 523 28. Macpherson AJ, McCoy KD, Johansen FE, Brandtzaeg P. The immune
524 geography of IgA induction and function. *Mucosal Immunol* 0000; 1:11-22.
- 525 29. van Ginkel FW, Nguyen HH, McGhee JR. Vaccines for mucosal immunity to
526 combat emerging infectious diseases. *Emerg Infect Dis* 2000; 6:123-32.
- 527 30. Talsma SS, Babensee JE, Murthy N, Williams IR. Development and in vitro
528 validation of a targeted delivery vehicle for DNA vaccines. *J Controlled Release*
529 2006; 112:271-9.
- 530 31. Russell-Jones GJ. Oral vaccine delivery. *J Controlled Release* 2000; 65:49-
531 54.
- 532 32. Burgdorf S, Kautz A, Böhnert V, Knolle PA, Kurts C. Distinct pathways of
533 antigen uptake and intracellular routing in CD4 and CD8 T cell activation. *Science*
534 (New York, NY) 2007; 316:612-6.
- 535 33. Brandtzaeg P. Nature and function of gastrointestinal antigen-presenting
536 cells. *Allergy* 2001; 56:16-20.
- 537 34. Diebold SS, Cotten M, Koch N, Zenke M. MHC class II presentation of
538 endogenously expressed antigens by transfected dendritic cells. *Gene Ther* 2001;
539 8:487-93.
- 540 35. Guy B. The perfect mix: recent progress in adjuvant research. *Nat Rev*
541 *Micro* 2007; 5:505-17.
- 542 36. Sansonetti PJ, Di Santo JP. Debugging how Bacteria Manipulate the
543 Immune Response. *Immunity* 2007; 26:149-61.
- 544 37. Khader SA, Bell GK, Pearl JE, Fountain JJ, Rangel-Moreno J, Cilley GE, Shen
545 F, Eaton SM, Gaffen SL, Swain SL, et al. IL-23 and IL-17 in the establishment of
546 protective pulmonary CD4(+) T cell responses after vaccination and during
547 *Mycobacterium tuberculosis* challenge. *Nat Immunol* 2007; 8:369-77.
- 548 38. Keijzer C, Haijema BJ, Meijerhof T, Voorn P, de Haan A, Leenhouts K, van
549 Roosmalen ML, van Eden W, Broere F. Inactivated influenza vaccine adjuvanted

550 with Bacterium-like particles induce systemic and mucosal influenza A virus
551 specific T-cell and B-cell responses after nasal administration in a TLR2
552 dependent fashion. *Vaccine* 2014; 32:2904-10.

553 39. Rathore JS, Wang Y. Protective role of Th17 cells in pulmonary infection.
554 *Vaccine* 2016; 34:1504-14.

555 40. Zygmunt BM, Rharbaoui F, Groebe L, Guzman CA. Intranasal
556 Immunization Promotes Th17 Immune Responses. *J Immunol* 2009; 183:6933-8.

557 41. Maroof A, Yorgensen YM, Li YF, Evans JT. Intranasal Vaccination Promotes
558 Detrimental Th17 Mediated Immunity against Influenza Infection. *PLoS Path*
559 2014; 10.

560 42. McKinstry KK, Strutt TM, Buck A, Curtis JD, Dibble JP, Huston G, Tighe M,
561 Hamada H, Sell S, Dutton RW, et al. IL-10 Deficiency Unleashes an Influenza-
562 Specific Th17 Response and Enhances Survival against High-Dose Challenge. *J*
563 *Immunol* 2009; 182:7353-63.

564 43. Hamada H, Garcia-Hernandez MD, Reome JB, Misra SK, Strutt TM,
565 McKinstry KK, Cooper AM, Swain SL, Dutton RW. Tc17, a Unique Subset of CD8 T
566 Cells That Can Protect against Lethal Influenza Challenge. *J Immunol* 2009;
567 182:3469-81.

568 44. Wang R, Epstein J, Baraceros FM, Gorak EJ, Charoenvit Y, Carucci DJ,
569 Hedstrom RC, Rahardjo N, Gay T, Hobart P, et al. Induction of CD4(+) T cell-
570 dependent CD8(+) type 1 responses in humans by a malaria DNA vaccine. *Proc*
571 *Natl Acad Sci U S A* 2001; 98:10817-22.

572 45. Srikiatkachorn A, Chang W, Braciale TJ. Induction of Th-1 and Th-2
573 Responses by Respiratory Syncytial Virus Attachment Glycoprotein Is Epitope
574 and Major Histocompatibility Complex Independent. *J Virol* 1999; 73:6590-7.

575 46. Haglund K, Leiner I, Kerkusiek K, Buonocore L, Pamer E, Rose JK. High-level
576 primary CD8(+) T-cell response to human immunodeficiency virus type 1 gag
577 and env generated by vaccination with recombinant vesicular stomatitis viruses.
578 *J Virol* 2002; 76:2730-8.

579 47. Boyer JD, Cohen AD, Vogt S, Schumann K, Nath B, Ahn L, Lacy K, Bagarazzi
580 ML, Higgins TJ, Baine Y, et al. Vaccination of seronegative volunteers with a
581 human immunodeficiency virus type 1 env/rev DNA vaccine induces antigen-
582 specific proliferation and lymphocyte production of beta-chemokines. *J Infect Dis*
583 2000; 181:476-83.

584 48. D'Souza S, Romano M, Korf J, Wang X-M, Adnet P-Y, Huygen K. Partial
585 Reconstitution of the CD4(+)-T-Cell Compartment in CD4 Gene Knockout Mice
586 Restores Responses to Tuberculosis DNA Vaccines. *Infect Immun* 2006; 74:2751-
587 9.

588 49. Walsh KP, Mills KHG. Dendritic cells and other innate determinants of T
589 helper cell polarisation. *Trends Immunol*; 34:521-30.

590 50. McKenzie Andrew NJ, Spits H, Eberl G. Innate Lymphoid Cells in
591 Inflammation and Immunity. *Immunity* 2014; 41:366-74.

592 51. Artis D, Spits H. The biology of innate lymphoid cells. *Nature* 2015;
593 517:293-301.

594 52. von Burg N, Turchinovich G, Finke D. Maintenance of Immune
595 Homeostasis through ILC/T Cell Interactions. *Frontiers in Immunology* 2015;
596 6:416.

597 53. Luci C, Bekri S, Bihl F, Pini J, Bourdely P, Nouhen K, Malgogne A, Walzer T,
598 Braud VM, Anjuère F. NKp46+ Innate Lymphoid Cells Dampen Vaginal CD8 T Cell

599 Responses following Local Immunization with a Cholera Toxin-Based Vaccine.
 600 PLoS ONE 2015; 10:e0143224.
 601 54. Zingoni A, Sornasse T, Cocks BG, Tanaka Y, Santoni A, Lanier LL. Cross-
 602 talk between activated human NK cells and CD4(+) T cells via OX40-OX40 ligand
 603 interactions. J Immunol 2004; 173:3716-24.
 604 55. Mirchandani AS, Besnard AG, Yip E, Scott C, Bain CC, Cerovic V, Salmond
 605 RJ, Liew FY. Type 2 Innate Lymphoid Cells Drive CD4(+) Th2 Cell Responses. J
 606 Immunol 2014; 192:2442-8.
 607 56. Sakaguchi S, Wing K, Miyara M. Regulatory T cells - a brief history and
 608 perspective. Eur J Immunol 2007; 37:S116-S23.
 609 57. Ramirez K, Wahid R, Richardson C, Bargatze RF, El-Kamary SS, Sztein MB,
 610 Pasetti MF. Intranasal vaccination with an adjuvanted Norwalk virus-like particle
 611 vaccine elicits antigen-specific B memory responses in human adult volunteers.
 612 Clin Immunol 2012; 144:98-108.
 613 58. Sealy R, Jones BG, Surman SL, Hurwitz JL. Robust IgA and IgG-producing
 614 antibody forming cells in the diffuse NALT and lungs of Sendai virus-vaccinated
 615 cotton rats associate with rapid protection against human parainfluenza virus-
 616 type 1. Vaccine 2010; 28:6749-56.
 617 59. Fujikuyama Y, Tokuhara D, Kataoka K, Gilbert RS, McGhee JR, Yuki Y,
 618 Kiyono H, Fujihashi K. Novel vaccine development strategies for inducing
 619 mucosal immunity. Expert Rev Vaccines 2012; 11:367-79.
 620 60. Simon JK, Ramirez K, Cuberos L, Campbell JD, Viret JF, Muñoz A, Lagos R,
 621 Levine MM, Pasetti MF. Mucosal IgA Responses in Healthy Adult Volunteers
 622 following Intranasal Spray Delivery of a Live Attenuated Measles Vaccine.
 623 Clinical and Vaccine Immunology : CVI 2011; 18:355-61.
 624 61. Lijek RS, Luque SL, Liu Q, Parker D, Bae T, Weiser JN. Protection from the
 625 acquisition of Staphylococcus aureus nasal carriage by cross-reactive antibody to
 626 a pneumococcal dehydrogenase. Proc Natl Acad Sci U S A 2012; 109:13823-8.
 627 62. Jang YH, Byun YH, Lee YJ, Lee YH, Lee K-H, Seong BL. Cold-Adapted
 628 Pandemic 2009 H1N1 Influenza Virus Live Vaccine Elicits Cross-Reactive
 629 Immune Responses against Seasonal and H5 Influenza A Viruses. J Virol 2012;
 630 86:5953-8.
 631 63. Motohashi S, Okamoto Y, Yoshino I, Nakayama T. Anti-tumor immune
 632 responses induced by iNKT cell-based immunotherapy for lung cancer and head
 633 and neck cancer. Clin Immunol 2011; 140:167-76.
 634 64. Xiao C, Davis FJ, Chauhan BC, Viola KL, Lacor PN, Velasco PT, Klein WL,
 635 Chauhan NB. Brain Transit and Ameliorative Effects of Intranasally Delivered
 636 Anti-Amyloid-beta Oligomer Antibody in 5XFAD Mice. J Alzheimers Dis 2013;
 637 35:777-88.
 638 65. Keijzer C, van der Zee R, van Eden W, Broere F. Treg inducing adjuvants
 639 for therapeutic vaccination against chronic inflammatory diseases. Frontiers in
 640 Immunology 2013; 4.
 641 66. Sakaguchi S, Miyara M, Costantino CM, Hafler DA. FOXP3+ regulatory T
 642 cells in the human immune system. Nat Rev Immunol 2010; 10:490-500.
 643 67. Weiner HL, da Cunha AP, Quintana F, Wu H. Oral tolerance. Immunol Rev
 644 2011; 241:241-59.
 645 68. Keijzer C, Spiering R, Silva AL, van Eden W, Jiskoot W, Vervelde L, Broere
 646 F. PLGA nanoparticles enhance the expression of retinaldehyde dehydrogenase

enzymes in dendritic cells and induce FoxP3⁺ T-cells in vitro. *J Controlled Release* 2013; 168:35-40.

69. Li H, Ding Y, Yi G, Zeng Q, Yang W. Establishment of nasal tolerance to heat shock protein-60 alleviates atherosclerosis by inducing TGF- β -dependent regulatory T cells. *Journal of Huazhong University of Science and Technology [Medical Sciences]* 2012; 32:24-30.

70. Klingenberg R, Lebens M, Hermansson A, Fredrikson GN, Strodthoff D, Rudling M, Ketelhuth DFJ, Gerdes N, Holmgren J, Nilsson J, et al. Intranasal Immunization With an Apolipoprotein B-100 Fusion Protein Induces Antigen-Specific Regulatory T Cells and Reduces Atherosclerosis. *Arteriosclerosis Thrombosis and Vascular Biology* 2010; 30:946-U148.

71. Broere F, Wieten L, Koerkamp EIK, van Roon JAG, Guichelaar T, Lafeber F, van Eden W. Oral or nasal antigen induces regulatory T cells that suppress arthritis and proliferation of arthritogenic T cells in joint draining lymph nodes. *J Immunol* 2008; 181:899-906.

72. Djupesland PG. Nasal drug delivery devices: characteristics and performance in a clinical perspective—a review. *Drug Delivery and Translational Research* 2013; 3:42-62.

73. Wang SH, Kirwan SM, Abraham SN, Staats HF, Hickey AJ. Stable Dry Powder Formulation for Nasal Delivery of Anthrax Vaccine. *J Pharm Sci* 2012; 101:31-47.

74. McInnes FJ, Thapa P, Baillie AJ, Welling PG, Watson DG, Gibson I, Nolan A, Stevens HNE. In vivo evaluation of nicotine lyophilised nasal insert in sheep. *Int J Pharm* 2005; 304:72-82.

75. Pattani A, McKay PF, Curran RM, McCaffrey J, Gupta PN, Lowry D, Kett VL, Shattock RJ, McCarthy HO, Malcolm RK. Molecular investigations into vaginal immunization with HIV gp41 antigenic construct H4A in a quick release solid dosage form. *Vaccine* 2012; 30:2778-85.

76. Bachmann MF, Jennings GT. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. *Nat Rev Immunol* 2010; 10:787-96.

77. Peek LJ, Middaugh CR, Berkland C. Nanotechnology in vaccine delivery. *Adv Drug Deliv Rev* 2008; 60:915-28.

78. Koping-Hoggard M, Sanchez A, Alonso MJ. Nanoparticles as carriers for nasal vaccine delivery. *Expert Review of Vaccines* 2005; 4:185-96.

79. Slütter B, Bal S, Keijzer C, Mallants R, Hagenaars N, Que I, Kaijzel E, van Eden W, Augustijns P, Löwik C, et al. Nasal vaccination with N-trimethyl chitosan and PLGA based nanoparticles: Nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen. *Vaccine* 2010; 28:6282-91.

80. Jain AK, Goyal AK, Gupta PN, Khatri K, Mishra N, Mehta A, Mangal S, Vyas SP. Synthesis, characterization and evaluation of novel triblock copolymer based nanoparticles for vaccine delivery against hepatitis B. *J Controlled Release* 2009; 136:161-9.

81. Jain A, Massey AS, Yusuf H, McDonald DM, McCarthy H, Kett V. Development of polymeric-cationic peptide composite nanoparticles, a nanoparticle-in- nanoparticle system for controlled gene delivery. *International Journal of Nanomedicine* 2015; In press.

- 694 82. Nochi T, Yuki Y, Takahashi H, Sawada S-i, Mejima M, Kohda T, Harada N,
695 Kong IG, Sato A, Kataoka N, et al. Nanogel antigenic protein-delivery system for
696 adjuvant-free intranasal vaccines. *Nat Mater* 2010; 9:572-8.
- 697 83. Jesus S, Soares E, Costa J, Borchard G, Borges O. Immune response elicited
698 by an intranasally delivered HBsAg low-dose adsorbed to poly-epsilon-
699 caprolactone based nanoparticles. *Int J Pharm* 2016; 504:59-69.
- 700 84. de Jonge MI, Hamstra HJ, Jiskoot W, Roholl P, Williams NA, Dankert J,
701 Alphen Lv, van der Ley P. Intranasal immunisation of mice with liposomes
702 containing recombinant meningococcal OpaB and OpaJ proteins. *Vaccine* 2004;
703 22:4021-8.
- 704 85. Wang D, Christopher ME, Nagata LP, Zabielski MA, Li H, Wong JP, Samuel
705 J. Intranasal immunization with liposome-encapsulated plasmid DNA encoding
706 influenza virus hemagglutinin elicits mucosal, cellular and humoral immune
707 responses. *J Clin Virol* 2004; 31, Supplement 1:99-106.
- 708 86. Khatri K, Goya AK, Gupta PN, Mishra N, Mehta A, Vyas SP. Surface
709 modified liposomes for nasal delivery of DNA vaccine. *Vaccine* 2008; 26:2225-33.
- 710 87. Amin M, Jaafari MR, Tafaghodi M. Impact of chitosan coating of anionic
711 liposomes on clearance rate, mucosal and systemic immune responses following
712 nasal administration in rabbits. *Colloids and Surfaces B-Biointerfaces* 2009;
713 74:225-9.
- 714 88. Heurtault B, Frisch B, Pons F. Liposomes as delivery systems for nasal
715 vaccination: strategies and outcomes. *Expert Opinion on Drug Delivery* 2010;
716 7:829-44.
- 717 89. Wang HW, Jiang PL, Lin SF, Lin HJ, Ou KL, Deng WP, Lee LW, Huang YY,
718 Liang PH, Liu DZ. Application of galactose-modified liposomes as a potent
719 antigen presenting cell targeted carrier for intranasal immunization. *Acta*
720 *Biomater* 2013; 9:5681-8.
- 721 90. Fan Y, Sahdev P, Ochyl LJ, J. Akerberg J, Moon JJ. Cationic liposome-
722 hyaluronic acid hybrid nanoparticles for intranasal vaccination with subunit
723 antigens. *J Controlled Release* 2015; 208:121-9.
- 724 91. Chen KH, Di Sabatino M, Albertini B, Passerini N, Kett VL. The effect of
725 polymer coatings on physicochemical properties of spray-dried liposomes for
726 nasal delivery of BSA. *Eur J Pharm Sci* 2013; 50:312-22.
- 727 92. Glück U, Gebbers J-O, Glück R. Phase 1 Evaluation of Intranasal Virosomal
728 Influenza Vaccine with and without Escherichia coli Heat-Labile Toxin in Adult
729 Volunteers. *J Virol* 1999; 73:7780-6.
- 730 93. Gluck R. Preclinical and clinical evaluation of a new virosomal intranasal
731 influenza vaccine. In: Osterhaus ADM, Cox N, Hampson AW, eds. *Options for the*
732 *Control of Influenza Iv*, 2001:969-78.
- 733 94. Cusi MG, Zurbriggen R, Valassina M, Bianchi S, Durrer P, Valensin PE,
734 Donati M, Gluck R. Intranasal immunization with mumps virus DNA vaccine
735 delivered by influenza virosomes elicits mucosal and systemic immunity.
736 *Virology* 2000; 277:111-8.
- 737 95. Durrer P, Gluck U, Spyr C, Lang AB, Zurbriggen R, Herzog C, Gluck R.
738 Mucosal antibody response induced with a nasal virosome-based influenza
739 vaccine. *Vaccine* 2003; 21:4328-34.
- 740 96. Salleras L, Dominguez A, Pumarola T, Prat A, Marcos MA, Garrido P,
741 Artigas R, Bau A, Brotons J, Bruna X, et al. Effectiveness of virosomal subunit
742 influenza vaccine in preventing influenza-related illnesses and its social and

743 economic consequences in children aged 3-14 years: A prospective cohort study.
 744 Vaccine 2006; 24:6638-42.
 745 97. Lambkin R, Oxford JS, Bossuyt S, Mann A, Metcalfe IC, Herzog C, Viret JF,
 746 Gluck R. Strong local and systemic protective immunity induced in the ferret
 747 model by an intranasal virosome-formulated influenza subunit vaccine. Vaccine
 748 2004; 22:4390-6.
 749 98. Hossain MJ, Bourgeois M, Quan F-S, Lipatov AS, Song J-M, Chen L-M,
 750 Compans RW, York I, Kang S-M, Donis RO. Virus-Like Particle Vaccine Containing
 751 Hemagglutinin Confers Protection against 2009 H1N1 Pandemic Influenza.
 752 Clinical and Vaccine Immunology 2011; 18:2010-7.
 753 99. Herbst-Kralovetz M, Mason HS, Chen Q. Norwalk virus-like particles as
 754 vaccines. Expert Review of Vaccines 2010; 9:299-307.
 755 100. Hagenslaars N, Mastrobattista E, Glansbeek H, Heldens J, van den Bosch H,
 756 Schijns V, Betbeder D, Vromans H, Jiskoot W. Head-to-head comparison of four
 757 nonadjuvanted inactivated cell culture-derived influenza vaccines: Effect of
 758 composition, spatial organization and immunization route on the
 759 immunogenicity in a murine challenge model. Vaccine 2008; 26:6555-63.
 760 101. de Jonge J, Leenhouts JM, Holtrop M, Schoen P, Scherrer P, Cullis PR,
 761 Wilschut J, Huckriede A. Cellular gene transfer mediated by influenza virosomes
 762 with encapsulated plasmid DNA. Biochem J 2007; 405:41-9.
 763 102. Cusi MG. Applications of influenza virosomes as a delivery system. Human
 764 Vaccines 2006; 2:1-7.
 765 103. Lai SK, Wang Y-Y, Hanes J. Mucus-penetrating nanoparticles for drug and
 766 gene delivery to mucosal tissues. Adv Drug Del Rev 2009; 61:158-71.
 767 104. Singh M, Briones M, O'Hagan DT. A novel bioadhesive intranasal delivery
 768 system for inactivated influenza vaccines. J Controlled Release 2001; 70:267-76.
 769 105. Stephenson I, Nicholson KG, Hoschler K, Zambon MC, Hancock K, DeVos J,
 770 Katz JM, Praus M, Banzhoff A. Antigenically distinct MF59-adjuvanted vaccine to
 771 boost immunity to H5N1. N Engl J Med 2008; 359:1631-3.
 772 106. Schultze V, D'Agosto V, Wack A, Novicki D, Zorn J, Hennig R. Safety of
 773 MF59™ adjuvant. Vaccine 2008; 26:3209-22.
 774 107. McAleer JP, Vella AT. Educating CD4 T cells with vaccine adjuvants:
 775 lessons from lipopolysaccharide. Trends Immunol 2010; 31:429-35.
 776 108. Zonneveld-Huijssoon E, van Wijk F, Roord S, Delemarre E, Meerding J, de
 777 Jager W, Klein M, Raz E, Albani S, Kuis W, et al. TLR9 agonist CpG enhances
 778 protective nasal HSP60 peptide vaccine efficacy in experimental autoimmune
 779 arthritis. Ann Rheum Dis 2012; 71:1706-15.
 780 109. Velasquez LS, Hjelm BE, Arntzen CJ, Herbst-Kralovetz MM. An intranasally
 781 delivered Toll-like receptor 7 agonist elicits robust systemic and mucosal
 782 responses to Norwalk virus-like particles. Clin Vaccine Immunol 2010; 17:1850-
 783 8.
 784 110. Sui Z, Chen Q, Wu R, Zhang H, Zheng M, Wang H, Chen Z. Cross-protection
 785 against influenza virus infection by intranasal administration of M2-based
 786 vaccine with chitosan as an adjuvant. Arch Virol 2010; 155:535-44.
 787 111. Noda K, Kodama S, Umemoto S, Abe N, Hirano T, Suzuki M. Nasal
 788 vaccination with P6 outer membrane protein and alpha-galactosylceramide
 789 induces nontypeable Haemophilus influenzae-specific protective immunity
 790 associated with NKT cell activation and dendritic cell expansion in nasopharynx.
 791 Vaccine 2010; 28:5068-74.

792 112. Miyata T, Harakuni T, Tsuboi T, Sattabongkot J, Kohama H, Tachibana M,
793 Matsuzaki G, Torii M, Arakawa T. Plasmodium vivax ookinete surface protein
794 Pvs25 linked to cholera toxin B subunit induces potent transmission-blocking
795 immunity by intranasal as well as subcutaneous immunization. Infect Immun
796 2010; 78:3773-82.

797 113. Freytag LC, Clements JD. Mucosal adjuvants. Vaccine 2005; 23:1804-13.

798 114. Mutsch M, Zhou W, Rhodes P, Bopp M, Chen RT, Linder T, Spyr C,
799 Steffen R. Use of the Inactivated Intranasal Influenza Vaccine and the Risk of
800 Bell's Palsy in Switzerland. N Engl J Med 2004; 350:896-903.

801 115. van Ginkel FW, Jackson RJ, Yuki Y, McGhee JR. Cutting edge: the mucosal
802 adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J
803 Immunol 2000; 165:4778-82.

804 116. Gluck R, Mischler R, Durrer P, Furer E, Lang AB, Herzog C, Cryz SJ, Jr.
805 Safety and immunogenicity of intranasally administered inactivated trivalent
806 virosome-formulated influenza vaccine containing Escherichia coli heat-labile
807 toxin as a mucosal adjuvant. J Infect Dis 2000; 181:1129-32.

808 117. Kanerva M, Mannonen L, Pliipainen H, Peltomaa M, Vaheri A, Pitkaranta
809 A. Search for herpesviruses in cerebrospinal fluid of facial palsy patients by PCR.
810 Acta Otolaryngol (Stockh) 2007; 127:775-9.

811 118. Kiura K, Kataoka H, Yasuda M, Inoue N, Shibata K. The diacylated
812 lipopeptide FSL-1 induces TLR2-mediated Th2 responses. FEMS Immunol Med
813 Microbiol 2006; 48:44-55.

814 119. Nyirenda MH, Sanvito L, Darlington PJ, O'Brien K, Zhang GX,
815 Constantinescu CS, Bar-Or A, Gran B. TLR2 Stimulation Drives Human Naive and
816 Effector Regulatory T Cells into a Th17-Like Phenotype with Reduced
817 Suppressive Function. J Immunol 2011; 187:2278-90.

818 120. Keijzer C, Slutter B, van der Zee R, Jiskoot W, van Eden W, Broere F. PLGA,
819 PLGA-TMC and TMC-TPP Nanoparticles Differentially Modulate the Outcome of
820 Nasal Vaccination by Inducing Tolerance or Enhancing Humoral Immunity. Plos
821 One 2011; 6:10.

822 121. Carter NJ, Curran MP. Live attenuated influenza vaccine (FluMist(R);
823 Fluenz): a review of its use in the prevention of seasonal influenza in children
824 and adults. Drugs 2011; 71:1591-622.

825 122. Watts PJ, Smith A. Re-formulating drugs and vaccines for intranasal
826 delivery: maximum benefits for minimum risks? Drug Discov Today 2011; 16:4-
827 7.

828 123. Kulkarni PS, Raut SK, Dhere RM. A post-marketing surveillance study of a
829 human live-virus pandemic influenza A (H1N1) vaccine (Nasovac ((R))) in India.
830 Human vaccines & immunotherapeutics 2013; 9:122-4.

831 124. Dhere R, Yeolekar L, Kulkarni P, Menon R, Vaidya V, Ganguly M, Tyagi P,
832 Barde P, Jadhav S. A pandemic influenza vaccine in India: from strain to sale
833 within 12 months. Vaccine 2011; 29 Suppl 1:A16-21.


834 125. Lycke N. Recent progress in mucosal vaccine development: potential and
835 limitations. Nature Reviews Immunology 2012; 12:592-605.

836 126. Control CfD. ACIP votes down use of LAIV for 2016-2017 flu season CDC
837 Press Release 2016.

838 127. Rudenko LG, Slepishkin AN, Monto AS, Kendal AP, Grigorieva EP,
839 Burtseva EP, Rekstin AR, Beljaev AL, Bragina VE, Cox N, et al. Efficacy Of Live

840 Attenuated And Inactivated Influenza Vaccines In Schoolchildren And Their
 841 Unvaccinated Contacts In Novgorod, Russia. *J Infect Dis* 1993; 168:881-7.
 842 128. Elveback LR, Fox JP, Ackerman E, Langworthy A, Boyd M, Gatewood L. An
 843 Influenza Simulation Model For Immunization Studies. *Am J Epidemiol* 1976;
 844 103:152-65.
 845 129. Damm O, Eichner M, Rose MA, Knuf M, Wutzler P, Liese JG, Kruger H,
 846 Greiner W. Public health impact and cost-effectiveness of intranasal live
 847 attenuated influenza vaccination of children in Germany. *Eur J Health Econ* 2015;
 848 16:471-88.
 849 130. Meeyai A, Praditsitthikorn N, Kotirum S, Kulpeng W, Putthasri W, Cooper
 850 BS, Teerawattananon Y. Seasonal Influenza Vaccination for Children in Thailand:
 851 A Cost-Effectiveness Analysis. *Plos Medicine* 2015; 12.
 852 131. SNBL. Nasal Flu vaccine using μ co™ System. 2015.
 853 132. Tepper SJ, Cady RK, Silberstein S, Messina J, Mahmoud RA, Djupesland PG,
 854 Shin P, Siffert J. AVP-825 Breath-Powered Intranasal Delivery System Containing
 855 22mg Sumatriptan Powder vs 100mg Oral Sumatriptan in the Acute Treatment
 856 of Migraines (The COMPASS Study): A Comparative Randomized Clinical Trial
 857 Across Multiple Attacks. *Headache* 2015; 55:621-35.
 858 133. Cady R. A novel intranasal breath-powered delivery system for
 859 sumatriptan: a review of technology and clinical application of the
 860 investigational product AVP-825 in the treatment of migraine. *Expert Opinion on*
 861 *Drug Delivery* 2015; 12:1565-77.
 862 134. Tepper SJ. Clinical Implications for Breath-Powered Powder Sumatriptan
 863 Intranasal Treatment. *Headache* 2013; 53:1341-9.
 864 135. Kurve. Kurve ViaNase Electronic Atomizer. Kurve Technology, Inc., 2016.
 865 136. Craft S, Baker LD, Montine TJ, Minoshima S, Watson GS, Claxton A,
 866 Arbuckle M, Callaghan M, Tsai E, Plymate SR, et al. Intranasal Insulin Therapy for
 867 Alzheimer Disease and Amnestic Mild Cognitive Impairment A Pilot Clinical Trial.
 868 *Arch Neurol* 2012; 69:29-38.
 869 137. Smith A, Perelman M, Hinchcliffe M. Chitosan: A promising safe and
 870 immune-enhancing adjuvant for intranasal vaccines. *Human vaccines &*
 871 *immunotherapeutics* 2014; 10:797-807.
 872 138. Le Grand R, Dereuddre-Bosquet N, Dispinseri S, Gosse L, Desjardins D,
 873 Shen XY, Tolazzi M, Ochsenbauer C, Saidi H, Tomaras G, et al. Superior Efficacy of
 874 a Human Immunodeficiency Virus Vaccine Combined with Antiretroviral
 875 Prevention in Simian-Human Immunodeficiency Virus-Challenged Nonhuman
 876 Primates. *J Virol* 2016; 90:5315-28.
 877 139. Lebre F, Borchard G, Faneca H, Pedroso de Lima MC, Borges O. Intranasal
 878 Administration of Novel Chitosan Nanoparticle/DNA Complexes Induces
 879 Antibody Response to Hepatitis B Surface Antigen in Mice. *Mol Pharm* 2016;
 880 13:472-82.
 881 140. Pawar D, Mangal S, Goswami R, Jaganathan KS. Development and
 882 characterization of surface modified PLGA nanoparticles for nasal vaccine
 883 delivery: Effect of mucoadhesive coating on antigen uptake and immune
 884 adjuvant activity. *Eur J Pharm Biopharm* 2013; 85:550-9.
 885 141. Khatrri K, Goyal AK, Gupta PN, Mishra N, Mehta A, Vyas SP. Surface
 886 modified liposomes for nasal delivery of DNA vaccine. *Vaccine* 2008; 26:2225-33.
 887 142. Pan L, Zhang Z, Lv J, Zhou P, Hu W, Fang Y, Chen H, Liu X, Shao J, Zhao F, et
 888 al. Induction of mucosal immune responses and protection of cattle against


889 direct-contact challenge by intranasal delivery with foot-and-mouth disease
890 virus antigen mediated by nanoparticles. Int J Nanomedicine 2014; 9:5603-18.
891 143. Grassin-Delyle S, Buenestado A, Naline E, Faisy C, Blouquit-Laye S,
892 Couderc LJ, Le Guen M, Fischler M, Devillier P. Intranasal drug delivery: an
893 efficient and non-invasive route for systemic administration: focus on opioids.
894 Pharmacol Ther 2012; 134:366-79.
895



898

899

Figure 2



900

901

902

903

Figure 3

